Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)
Close on Nov 17, 2026Market cap $73.93MP/E –Yield –
Coherus Oncology operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Coherus Oncology's operating cash flow for the twelve months ending Jun 30, 2026 was -$186.03M. For fiscal 2025 it was -$138.51M. The highest annual figure on record is $154.15M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$138.51M | – |
| FY2024 | Dec 31, 2024 | -$20.44M | – |
| FY2023 | Dec 31, 2023 | -$174.88M | – |
| FY2022 | Dec 31, 2022 | -$241.12M | – |
| FY2021 | Dec 31, 2021 | -$37.43M | -124.3% |
| FY2020 | Dec 31, 2020 | $154.15M | +443.6% |
| FY2019 | Dec 31, 2019 | $28.36M | – |
| FY2018 | Dec 31, 2018 | -$159.27M | – |
| FY2017 | Dec 31, 2017 | -$200.29M | – |
| FY2016 | Dec 31, 2016 | -$252.55M | – |
| FY2015 | Dec 31, 2015 | -$107.99M | – |
| FY2014 | Dec 31, 2014 | -$23.93M | -255.1% |
| FY2013 | Dec 31, 2013 | $15.42M | – |
| FY2012 | Dec 31, 2012 | -$18.25M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$62.09M | – |
| Q1 FY2026 | Mar 31, 2026 | -$57.89M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.72M | -168.9% |
| Q3 FY2025 | Sep 30, 2025 | -$46.34M | – |
| Q2 FY2025 | Jun 30, 2025 | -$46.63M | -178.1% |
| Q1 FY2025 | Mar 31, 2025 | -$25.83M | – |
| Q4 FY2024 | Dec 31, 2024 | $28.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$62.02M | – |
| Q2 FY2024 | Jun 30, 2024 | $59.73M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.94M | – |
| Q3 FY2023 | Sep 30, 2023 | -$54.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$38.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$68.73M | – |
| Q4 FY2022 | Dec 31, 2022 | -$99.95M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.09M | -370.5% |
| Q2 FY2022 | Jun 30, 2022 | -$50.04M | – |
| Q1 FY2022 | Mar 31, 2022 | -$54.05M | -4053.5% |
| Q4 FY2021 | Dec 31, 2021 | -$52.32M | -258.0% |
| Q3 FY2021 | Sep 30, 2021 | $13.71M | -71.0% |
| Q2 FY2021 | Jun 30, 2021 | -$188.00K | -100.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.37M | -89.9% |
| Q4 FY2020 | Dec 31, 2020 | $33.12M | +87.0% |
| Q3 FY2020 | Sep 30, 2020 | $47.35M | -13.8% |
| Q2 FY2020 | Jun 30, 2020 | $60.19M | +374.8% |
| Q1 FY2020 | Mar 31, 2020 | $13.48M | – |
| Q4 FY2019 | Dec 31, 2019 | $17.71M | – |
| Q3 FY2019 | Sep 30, 2019 | $54.95M | – |
| Q2 FY2019 | Jun 30, 2019 | $12.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$56.98M | – |
| Q4 FY2018 | Dec 31, 2018 | -$47.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$42.79M | – |
| Q2 FY2018 | Jun 30, 2018 | -$35.53M | – |
| Q1 FY2018 | Mar 31, 2018 | -$33.58M | – |
| Q4 FY2017 | Dec 31, 2017 | -$29.92M | – |
| Q3 FY2017 | Sep 30, 2017 | -$41.51M | – |
| Q2 FY2017 | Jun 30, 2017 | -$55.57M | – |
| Q1 FY2017 | Mar 31, 2017 | -$73.28M | – |
| Q4 FY2016 | Dec 31, 2016 | -$86.89M | – |
| Q3 FY2016 | Sep 30, 2016 | -$61.95M | – |
See a number that looks wrong?